Table B in [S3 Appendix](#pone.0162229.s003){ref-type="supplementary-material"} of the Supplementary Material gives a reference for each of the data sources available in the published literature. Data sources that cannot be found publicly are also listed with information on whether microdata was supplied, whether the study involved rapid assessment methodology and other notes that may assist the reader. Other data are available from the Global Vision Database (<http://www.globalvisiondata.org/>). Some principal investigators of studies that are included in this database supplied detailed data on condition that only summary data would be publicly accessible hence the restriction on complete access to the completely disaggregated dataset. These data are owned by the principal investigators and cannot be made publicly available without permission of the Global Vision Database Data Access Committee. The Global Vision Database data files are stored securely at Anglia Ruskin University, Cambridge, UK, according to the university\'s information security guidelines. Qualified researchers who wish to request access to the third party data may contact the Global Vision Database through the website (<http://www.globalvisiondata.org/contact.html>) or using the following contact information: Professor Shahina Pardhan. Email: <shahina.pardhan@anglia.ac.uk>. Address: Vision & Eye Research Unit, Postgraduate Medical Institute, Anglia Ruskin University, East Road, Cambridge, UK.

Introduction {#sec005}
============

Previous population-based investigations have shown that glaucoma is one of the most common, and thus most important, causes for vision loss worldwide \[[@pone.0162229.ref001]--[@pone.0162229.ref034]\]. Previous estimations of global burden of glaucoma were based on meta-analyses which did not include studies, as far as available, from all regions of the world, which did not include all available population-based studies, which did not assess a change during the last 2 decades, or which mostly reported on the prevalence of the disease \[[@pone.0162229.ref001]--[@pone.0162229.ref003]\]. Many of the population-based glaucoma studies did not report on the number of people blind or visually impaired due glaucoma. For public health purposes, however, the number of patients functionally affected is more important than the number of patients with any stage of the disease. For the individual patient and thus for the society, the burden of a disease is more important than just the presence of a disease including its early stages. We therefore conducted this meta-analysis of all available population-based studies performed worldwide within the last two decades to estimate the number of people affected by blindness (defined as presenting visual acuity \<3/60) and moderately to severe visual impairment (MSVI; presenting visual acuity \<6/18, ≥3/60) due to glaucoma, to assess changes in that figures during the period from 1990 to 2010, to examine regional differences in the prevalence of glaucoma related blindness and MSVI, and finally to compare the number of blind and visually impaired people with glaucoma with the number of people blind and visually impaired due to other diseases.

Methods {#sec006}
=======

In a systemic literature research we used the systems of Medline, Embase and the WHO (World Health Organization) library information system to search for articles on vision loss and published in the period between 1980 and 2012. The methodology for this systematic review is described in [Fig 1](#pone.0162229.g001){ref-type="fig"} as a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart with a PRISMA checklist in [S1 Appendix](#pone.0162229.s001){ref-type="supplementary-material"}. The search strategy is presented in [S2 Appendix](#pone.0162229.s002){ref-type="supplementary-material"}. Out of primarily identified 14,908 relevant manuscripts, we selected 243 high-quality, population-based studies after review by an expert panel. The latter involved application of selection criteria that were based on population representativeness and clarity of visual acuity methods used. As described in detail recently, search terms included concepts to describe "blindness", "visual impairment", "population", "eye", "survey", and a list of ocular disorders \[[@pone.0162229.ref035]--[@pone.0162229.ref037]\]. Additional unpublished data sources were found by personal communication with researchers identified in the literature search. Population-based studies that reported prevalence of visual impairment and blindness disaggregated by cause (128 studies) provided the basic data to calculate the proportion of blindness and MSVI that were due to glaucoma, besides other causes such as cataract, macular degeneration, diabetic retinopathy, trachoma, or undercorrection of refractive error. A full list of data sources used for each cause has been presented recently (Table B in [S3 Appendix](#pone.0162229.s003){ref-type="supplementary-material"}) \[[@pone.0162229.ref037]\]. Two studies per region were available for 18 of the 21 GBD (Global Burden of Disease) Study regions, while only one study was identified for Central Europe. Eastern Europe and Central Africa did not have any study with cause-specific data. No study was identified for 126 of 191 countries. Data were extracted from published and unpublished reports into an electronic database (Microsoft Excel) by two investigators working independently with consistency checks in order to minimize data inputting errors. Extracted data included prevalence of predefined severities of vision loss by age, gender, country, region, and cause.

![PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart.](pone.0162229.g001){#pone.0162229.g001}

Stratifying by age, sex, and geographical region, we estimated trends in causes of vision impairment and included an analysis of uncertainties. For geographical stratification, we used the 21 regions defined in the GBD Study \[[@pone.0162229.ref038]\]. As part of the statistical analysis, we first identified and accessed the data and then estimated fractions for each cause. We stratified the results by the severity of vision impairment, sex, age, and region. We finally applied the cause fractions to the prevalence of all-cause presenting vision impairment \[[@pone.0162229.ref037]\]. The method has been described in detail previously \[[@pone.0162229.ref037]\].

For the statistical analysis, the Disease Modeling--Metaregression (DisMod-MR) model from the GBD Study was used to determine the fraction of vision impairment caused by glaucoma or due to other causes mentioned above (more detailed information is available in [S3 Appendix](#pone.0162229.s003){ref-type="supplementary-material"} with an explanation of country and regional groupings, Table A, and a full list of citations of the studies, Table B) \[[@pone.0162229.ref037]\]. Briefly, the DisMod-MR model is a negative binomial regression model which included the following elements: covariates that predicted the variation in the true proportion of vision impairment from each disease; fixed effects that adjusted for definitional differences (e.g. whether the causes of presenting vs. best-corrected vision impairment were reported); a hierarchical model structure which fitted random intercepts in individual countries derived from the data observed in the country, in its region, and in other regions based on the availability and consistency of country- and region-specific data; age-specific fixed-effects which allowed for a non-linear age pattern; and a fixed effect for data on males. For the assessment of the fractions of blindness and visual impairment which were caused by glaucoma, we fitted one DisMod-MR model and used three covariates: an indicator variable which described whether the data were for blindness or for MSVI, an indicator variable describing whether the data were based on presenting visual acuity or best-corrected visual acuity measurements, and a country-level covariate which reflected the health systems access. We made two sets of the prediction for glaucoma, one for best-corrected blindness and one for best-corrected MSVI. Using the WHO reference population, we age-standardized the prevalences \[[@pone.0162229.ref039]\]. We also calculated the numbers of people with vision impairment and blindness caused by glaucoma. It reflected each region's population size and age structure.

Results {#sec007}
=======

Blindness caused by glaucoma was found to be present in 2.1 million (95% uncertainty interval (UI): 1.9, 2.6) people, and MSVI caused by glaucoma was detected for 4.2 million (95%UI: 3.7--5.8) million individuals ([Table 1](#pone.0162229.t001){ref-type="table"}). Taking into account that overall 32.4 million people were blind and 191 million people were vision impaired in 2010, glaucoma caused worldwide 6.6% (95%UI: 5.9, 7.9) of all causes for blindness in 2010 and 2.2% (95%UI: 2.0, 2.8) of all causes for MSVI ([Table 1](#pone.0162229.t001){ref-type="table"}) \[[@pone.0162229.ref035]\]. The percentage of blindness caused by glaucoma varied from \<5% in South Asia, East and West Sub-Saharan Africa, and Oceania, to 15.5% (9.5--21.9%) in Tropical Latin America.

10.1371/journal.pone.0162229.t001

###### Number of people (mean, 95% uncertainty interval) blind (presenting visual acuity \<3/60) or visually impaired (MSVI) (presenting visual acuity \<6/18, ≥3/60) due to glaucoma and the age-standardized prevalences (mean, 95% uncertainty interval) in different world regions in 2010.
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  World Region                   Blindness / Moderate to Severe Visual Impairment (MSVI) by Glaucoma   Total Population 2010   Number of People Affected in 2010   Age-Standardized Prevalence in People Aged 50+ Years in 2010   Percent of Blindness / Visual Impairment by Glaucoma in 2010                        
  ------------------------------ --------------------------------------------------------------------- ----------------------- ----------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- ------ ------ ------ ------------------
  World                          BLIND                                                                 6,890,000,000           2,129,010                           1,867,190                                                      2,631,980                                                      0.1%   0.1%   0.2%   6.6 (5.9, 7.9)
  Asia Pacific, High Income      BLIND                                                                 169,000,000             41,236                              21,680                                                         92,060                                                         0.0%   0.0%   0.1%   11.7 (7.1, 18.8)
  Asia, Central                  BLIND                                                                 68,800,000              16,146                              10,742                                                         26,920                                                         0.1%   0.1%   0.2%   12.0 (8.7, 17.2)
  Asia, East                     BLIND                                                                 1,190,000,000           280,664                             179,792                                                        445,252                                                        0.1%   0.1%   0.1%   5.4 (3.5, 8.5)
  Asia, South                    BLIND                                                                 1,120,000,000           493,126                             328,286                                                        787,091                                                        0.2%   0.2%   0.4%   4.7 (3.3, 7.5)
  Asia, Southeast                BLIND                                                                 460,000,000             195,036                             128,088                                                        280,470                                                        0.2%   0.1%   0.3%   5.6 (4.3, 8.2)
  Australasia                    BLIND                                                                 20,500,000              4,359                               2,279                                                          12,153                                                         0.0%   0.0%   0.1%   11.3 (6.8, 18.8)
  Caribbean                      BLIND                                                                 34,300,000              21,996                              13,683                                                         33,690                                                         0.2%   0.1%   0.3%   11.2 (8.0, 15.1)
  Europe, Central                BLIND                                                                 122,000,000             40,894                              28,224                                                         93,954                                                         0.1%   0.1%   0.2%   12.5 (9.1, 17.0)
  Europe, Eastern                BLIND                                                                 222,000,000             79,285                              39,916                                                         154,466                                                        0.1%   0.0%   0.2%   13.5 (8.6, 20.6)
  Europe, Western                BLIND                                                                 381,000,000             101,391                             65,985                                                         159,726                                                        0.0%   0.0%   0.1%   10.6 (8.2, 14.0)
  Latin America, Andean          BLIND                                                                 38,600,000              22,996                              13,920                                                         35,935                                                         0.3%   0.2%   0.4%   11.7 (7.9, 17.1)
  Latin America, Central         BLIND                                                                 166,000,000             118,569                             80,675                                                         177,954                                                        0.3%   0.2%   0.4%   13.0 (9.6, 18.2)
  Latin America, Southern        BLIND                                                                 48,900,000              28,401                              18,116                                                         50,815                                                         0.2%   0.1%   0.3%   12.6 (7.9, 19.3)
  Latin America, Tropical        BLIND                                                                 154,000,000             123,409                             65,267                                                         262,580                                                        0.3%   0.2%   0.6%   15.5 (9.6, 21.9)
  North Africa/Middle East       BLIND                                                                 301,000,000             300,578                             216,888                                                        434,025                                                        0.5%   0.4%   0.7%   9.6 (7.5, 13.2)
  North America, High Income     BLIND                                                                 281,000,000             50,464                              28,478                                                         90,572                                                         0.0%   0.0%   0.1%   10.7 (7.0, 15.7)
  Oceania                        BLIND                                                                 5,814,186               1,375                               704                                                            2,694                                                          0.2%   0.1%   0.4%   4.2 (2.5, 7.2)
  Sub-Saharan Africa, Central    BLIND                                                                 53,400,000              14,663                              7,574                                                          34,857                                                         0.2%   0.1%   0.5%   5.2 (3.4, 8.8)
  Sub-Saharan Africa, East       BLIND                                                                 208,000,000             83,252                              57,759                                                         121,613                                                        0.3%   0.2%   0.4%   4.0 (3.1, 5.4)
  Sub-Saharan Africa, South      BLIND                                                                 52,600,000              21,870                              10,551                                                         34,971                                                         0.3%   0.1%   0.4%   7.3 (5.2, 10.4)
  Sub-Saharan Africa, West       BLIND                                                                 201,000,000             91,532                              64,503                                                         129,601                                                        0.3%   0.2%   0.5%   4.4 (3.4, 5.9)
  World                          MSVI                                                                  6,890,000,000           4,209,790                           3,693,040                                                      5,808,270                                                      0.3%   0.2%   0.4%   2.2 (2.0, 2.8)
  Asia Pacific, High Income      MSVI                                                                  169,000,000             72,451                              41,009                                                         284,553                                                        0.1%   0.0%   0.3%   3.7 (2.3, 6.9)
  Asia, Central                  MSVI                                                                  68,800,000              42,894                              26,157                                                         91,467                                                         0.3%   0.2%   0.6%   3.6 (2.6, 5.4)
  Asia, East                     MSVI                                                                  1,190,000,000           519,648                             296,002                                                        911,581                                                        0.2%   0.1%   0.3%   1.6 (0.94, 2.5)
  Asia, South                    MSVI                                                                  1,120,000,000           1,111,183                           707,164                                                        1939,554                                                       0.5%   0.3%   0.8%   1.6 (1.0, 2.6)
  Asia, Southeast                MSVI                                                                  460,000,000             330,064                             227,354                                                        687,535                                                        0.3%   0.2%   0.7%   1.8 (1.3, 3.0)
  Australasia                    MSVI                                                                  20,500,000              14,724                              6,098                                                          41,810                                                         0.1%   0.1%   0.4%   3.2 (1.9, 5.9)
  Caribbean                      MSVI                                                                  34,300,000              52,416                              29,454                                                         85,792                                                         0.5%   0.3%   0.9%   4.3 (3.1, 6.4)
  Europe, Central                MSVI                                                                  122,000,000             128,461                             68,054                                                         265,300                                                        0.3%   0.1%   0.5%   3.9 (2.8, 6.0)
  Europe, Eastern                MSVI                                                                  222,000,000             263,377                             104,141                                                        592,790                                                        0.3%   0.1%   0.7%   4.5 (2.6, 7.7)
  Europe, Western                MSVI                                                                  381,000,000             252,546                             171,693                                                        484,709                                                        0.1%   0.1%   0.2%   3.4 (2.5, 4.9)
  Latin America, Andean          MSVI                                                                  38,600,000              62,579                              36,452                                                         107,134                                                        0.7%   0.4%   1.2%   4.5 (2.9, 7.5)
  Latin America, Central         MSVI                                                                  166,000,000             234,065                             157,738                                                        362,576                                                        0.6%   0.4%   0.9%   4.6 (3.2, 7.1)
  Latin America, Southern        MSVI                                                                  48,900,000              63,187                              36,186                                                         139,233                                                        0.3%   0.2%   0.8%   4.0 (2.5, 6.3)
  Latin America, Tropical        MSVI                                                                  154,000,000             250,589                             132,867                                                        420,236                                                        0.6%   0.3%   1.0%   5.2 (3.2, 8.4)
  North Africa/Middle East       MSVI                                                                  301,000,000             414,896                             262,711                                                        701,481                                                        0.6%   0.4%   1.1%   3.0 (2.1, 4.7)
  North America, High Income     MSVI                                                                  281,000,000             104,104                             68,661                                                         236,663                                                        0.1%   0.0%   0.2%   3.4 (2.3, 5.4)
  Oceania                        MSVI                                                                  5,814,186               3,389                               1,669                                                          6,666                                                          0.4%   0.2%   0.7%   1.4 (0.85, 2.5)
  Sub-Saharan Africa, Central    MSVI                                                                  53,400,000              26,745                              14,950                                                         62,450                                                         0.3%   0.2%   0.8%   1.9 (1.2, 3.3)
  Sub-Saharan Africa, East       MSVI                                                                  208,000,000             105,933                             76,706                                                         160,640                                                        0.3%   0.2%   0.5%   1.5 (1.1, 2.2)
  Sub-Saharan Africa, Southern   MSVI                                                                  52,600,000              24,600                              15,208                                                         49,832                                                         0.3%   0.2%   0.5%   2.6 (1.8, 4.0)
  Sub-Saharan Africa, West       MSVI                                                                  201,000,000             129,427                             92,406                                                         222,330                                                        0.4%   0.3%   0.7%   1.8 (1.3, 2.7)

From the baseline in 1990 to 2010 the number of individuals blind due to glaucoma increased by 0.8 million (95%UI: 0.7, 1.1) and the number of individuals with MSVI due to glaucoma increased by 2.3 million (95%UI: 2.1, 3.5) (Tables [1](#pone.0162229.t001){ref-type="table"} and [2](#pone.0162229.t002){ref-type="table"}). If only individuals with an age of 50+ years were included, the number of people blind due to glaucoma increased from 1.3 million (95%UI: 1.2, 1.6) in 1990 to 2.0 million (95%UI: 1.8, 2.5) in 2010, and the number of individuals with glaucoma related visual impairment increased from 1.9 million (95%UI: 1.5, 2.3) in 1990 to 3.8 million (95%UI: 3.3, 5.3) in 2010. Compared with 1990, the percentage of global blindness caused by glaucoma increased from 4.4% (4.0, 5.1) to 6.6% (Tables [1](#pone.0162229.t001){ref-type="table"} and [2](#pone.0162229.t002){ref-type="table"}). World regions with older populations such as the high-income regions, Southern Latin America, and Central and Eastern Europe, as compared to regions with younger populations showed a higher percentage of blindness caused by glaucoma in 1990 and in 2010 ([Table 1](#pone.0162229.t001){ref-type="table"}). The increase in the percentage of global blindness caused by glaucoma from 1990 to 2010 had taken place in all world regions without major difference between them (Tables [1](#pone.0162229.t001){ref-type="table"} and [2](#pone.0162229.t002){ref-type="table"}).

10.1371/journal.pone.0162229.t002

###### Number of people (mean, 95% uncertainty interval) blind (presenting visual acuity \<3/60) or visually impaired (MSVI) (presenting visual acuity \<6/18, ≥3/60) due to glaucoma and the age-standardized prevalences (mean, 95% uncertainty interval) in different world regions in 1990.
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  Region                                 Number of People Affected in 1990   Mean Difference in the Number of People Affected 2010--1990   Age-Standardized Prevalence in People Aged 50+ Years in 1990   Percent of Blindness / Visual Impairment by Glaucoma in 1990                                            
  ------------------------------ ------- ----------------------------------- ------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- --------- --------- ------ ------ ------ -------------------
  World                          BLIND   1316596                             1155344                                                       1573536                                                        812414                                                         711846    1058444   0,2%   0,1%   0,2%   4.4 (4.0, 5.1)
  Asia Pacific, High Income      BLIND   24203                               13897                                                         48421                                                          17033                                                          7783      43639     0,1%   0,0%   0,1%   9.0 (6.0, 12.8)
  Asia, Central                  BLIND   18340                               12302                                                         28142                                                          -2194                                                          -1560     -1222     0,2%   0,1%   0,3%   9.5 (7.3, 12.6)
  Asia, East                     BLIND   220.492                             145.928                                                       353.111                                                        60172                                                          33864     92141     0,1%   0,1%   0,2%   3.9 (2.6, 5.8)
  Asia, South                    BLIND   206493                              146182                                                        284448                                                         286633                                                         182104    502643    0,2%   0,1%   0,3%   2.4 (1.7, 3.3)
  Asia, Southeast                BLIND   102470                              68890                                                         141352                                                         92566                                                          59198     139118    0,2%   0,2%   0,3%   3.3 (2.6, 4.4)
  Australasia                    BLIND   3240                                2152                                                          8014                                                           1119                                                           127       4139      0,1%   0,0%   0,1%   9.6 (7.4, 13.1)
  Caribbean                      BLIND   17989                               12161                                                         25590                                                          4007                                                           1522      8100      0,3%   0,2%   0,4%   9.1 (7.3, 11.8)
  Europe, Central                BLIND   40973                               28957                                                         80175                                                          -79                                                            -733      13779     0,1%   0,1%   0,2%   10.2 (7.9, 13.3)
  Europe, Eastern                BLIND   100223                              49413                                                         171479                                                         -20938                                                         -9497     -17013    0,2%   0,1%   0,3%   10.8 (7.7, 15.4)
  Europe, Western                BLIND   104486                              76973                                                         166514                                                         -3095                                                          -10988    -6788     0,1%   0,0%   0,1%   9.0 (7.4, 11.3)
  Latin America, Andean          BLIND   12274                               7599                                                          18478                                                          10722                                                          6321      17457     0,3%   0,2%   0,5%   6.8 (5.0, 9.6)
  Latin America, Central         BLIND   68707                               49116                                                         97253                                                          49862                                                          31559     80701     0,4%   0,3%   0,5%   8.6 (6.7, 11.7)
  Latin America, Southern        BLIND   20923                               13656                                                         33269                                                          7478                                                           4460      17546     0,2%   0,1%   0,3%   9.3 (6.6, 12.6)
  Latin America, Tropical        BLIND   64043                               33539                                                         128981                                                         59366                                                          31728     133599    0,4%   0,2%   0,8%   9.2 (5.9, 14.0)
  North Africa / Middle East     BLIND   156025                              100468                                                        225966                                                         144553                                                         116420    208059    0,6%   0,4%   0,8%   5.6 (4.4, 7.6)
  North America, High Income     BLIND   40330                               25890                                                         65139                                                          10134                                                          2588      25433     0,0%   0,0%   0,1%   9.2 (6.7, 11.9)
  Oceania                        BLIND   701                                 368                                                           1267                                                           674                                                            336       1427      0,2%   0,1%   0,3%   2.8 (2.0, 4.1)
  Sub-Saharan Africa, Central    BLIND   8359                                4813                                                          17587                                                          6304                                                           2761      17270     0,2%   0,1%   0,5%   3.3 (2.4, 4.6)
  Sub-Saharan Africa, East       BLIND   42392                               30040                                                         56506                                                          40860                                                          27719     65107     0,3%   0,2%   0,4%   2.9 (2.4, 3.6)
  Sub-Saharan Africa, Southern   BLIND   15121                               7703                                                          22286                                                          6749                                                           2848      12685     0,4%   0,2%   0,5%   5.4 (4.2, 7.3)
  Sub-Saharan Africa, West       BLIND   49454                               34740                                                         67855                                                          42078                                                          29763     61746     0,3%   0,2%   0,5%   2.9 (2.4, 3.8)
  World                          MSVI    1880978                             1544298                                                       2335496                                                        2328812                                                        2148742   3472774   0,2%   0,2%   0,3%   1.2 (1.1, 1.5)
  Asia Pacific, High Income      MSVI    33651                               19846                                                         95198                                                          38800                                                          21163     189355    0,1%   0,0%   0,2%   2.3 (1.5, 3.5)
  Asia, Central                  MSVI    31447                               18045                                                         56188                                                          11447                                                          8112      35279     0,3%   0,2%   0,6%   2.3 (1.8, 3.3)
  Asia, East                     MSVI    267765                              139163                                                        435633                                                         251883                                                         156839    475948    0,1%   0,1%   0,2%   0.92 (0.57, 1.5)
  Asia, South                    MSVI    336127                              211531                                                        503752                                                         775056                                                         495633    1435802   0,3%   0,2%   0,4%   0.66 (0.47, 0.90)
  Asia, Southeast                MSVI    116945                              78579                                                         175589                                                         213119                                                         148775    511946    0,2%   0,2%   0,4%   0.83 (0.65, 1.1)
  Australasia                    MSVI    9028                                4311                                                          20390                                                          5696                                                           1787      21420     0,2%   0,1%   0,3%   2.4 (1.7, 3.4)
  Caribbean                      MSVI    31364                               16368                                                         43633                                                          21052                                                          13086     42159     0,5%   0,3%   0,8%   3.0 (2.2, 4.1)
  Europe, Central                MSVI    88984                               43131                                                         155615                                                         39477                                                          24923     109685    0,3%   0,1%   0,5%   2.5 (1.9, 3.3)
  Europe, Eastern                MSVI    206804                              96231                                                         351954                                                         56573                                                          7910      240836    0,3%   0,1%   0,5%   2.7 (1.8, 4.2)
  Europe, Western                MSVI    184746                              121141                                                        311166                                                         67800                                                          50552     173543    0,1%   0,1%   0,2%   2.3 (1.8, 3.0)
  Latin America, Andean          MSVI    22239                               12032                                                         34711                                                          40340                                                          24420     72423     0,5%   0,3%   0,8%   2.1 (1.4, 3.0)
  Latin America, Central         MSVI    97887                               58316                                                         148486                                                         136178                                                         99422     214090    0,5%   0,3%   0,8%   2.5 (1.9, 3.7)
  Latin America, Southern        MSVI    34980                               20728                                                         64235                                                          28207                                                          15458     74998     0,3%   0,2%   0,6%   2.4 (1.7, 3.7)
  Latin America, Tropical        MSVI    102190                              51076                                                         171029                                                         148399                                                         81791     249207    0,6%   0,3%   0,9%   2.7 (1.6, 4.5)
  North Africa/Middle East       MSVI    139327                              87028                                                         195413                                                         275569                                                         175683    506068    0,5%   0,3%   0,7%   1.4 (1.1, 1.9)
  North America, High Income     MSVI    67720                               46918                                                         122215                                                         36384                                                          21743     114448    0,1%   0,1%   0,1%   2.4 (1.7, 3.4)
  Oceania                        MSVI    1130                                572                                                           1785                                                           2259                                                           1097      4881      0,3%   0,1%   0,4%   0.73 (0.51, 1.1)
  Sub-Saharan Africa, Central    MSVI    10799                               5902                                                          20538                                                          15946                                                          9048      41912     0,3%   0,1%   0,5%   1.0 (0.71, 1.5)
  Sub-Saharan Africa, East       MSVI    41593                               30430                                                         57934                                                          64340                                                          46276     102706    0,3%   0,2%   0,4%   0.95 (0.76, 1.2)
  Sub-Saharan Africa, Southern   MSVI    10997                               7531                                                          17821                                                          13603                                                          7677      32011     0,3%   0,2%   0,4%   1.5 (1.1, 2.3)
  Sub-Saharan Africa, West       MSVI    45875                               30759                                                         65282                                                          83552                                                          61647     157048    0,3%   0,2%   0,4%   0.93 (0.71, 1.3)

Age-standardized prevalence of glaucoma related blindness was worldwide 0.1% (95%UI: 0.1, 02) in adults aged 50+ years in 2010, and the age-standardized prevalence of MSVI caused by glaucoma was worldwide 0.3% (95%UI: 0.2, 0.4) ([Table 1](#pone.0162229.t001){ref-type="table"}). Compared with 1990, the age-standardized prevalence of glaucoma-related blindness was reduced from 0.2% (95%UI: 0.1, 0.2) to 0.1% and the prevalence of glaucoma-related MSVI increased from 0.2% (95%UI: 0.2, 0.3) to 0.3% (Tables [1](#pone.0162229.t001){ref-type="table"} and [2](#pone.0162229.t002){ref-type="table"}).

With respect to sex, the age-standardized prevalence of glaucoma related blindness among women (0.1%; 95%UI: 0.1, 0.2) and men (0.1%; 95%UI: 0.1, 0.2) did not differ. The same held true for the age-standardized prevalence of MSVI due to glaucoma (0.3% (95%UI: 0.2, 0.4) in women versus 0.3% (95%UI: 0.3, 0.4) in men).

Discussion {#sec008}
==========

Glaucoma was the cause for blindness in 2.1 million people or 6.6% of overall 32.4 million blind people globally in 2010, and glaucoma was the cause for MSVI in 4.2 million people or 2.2% of overall 191 million people visually impaired in 2010 \[[@pone.0162229.ref036]\]. These figures are lower than those reported by Quigley and Broman who forecasted in 2005 that in 2010, bilateral glaucoma related blindness would affect 8.4 million people \[[@pone.0162229.ref002]\]. Quigley and Broman discussed the difference between their estimate and an estimate of 4.4 million that was the most recent estimate at the time by the WHO Vision Group published by Resnikoff et al. \[[@pone.0162229.ref040]\]. Quigley and Broman argued that the difference was due to methodological issues given that blindness prevalence surveys often assigned the most ''treatable" disease as the primary cause of blindness. It is often assumed that cataract is more treatable than glaucoma, which leads to an underestimation of glaucoma blindness. In the recent analysis of global blindness, glaucoma ranked third together with macular degeneration (both: 6.6% of all blind people globally) after cataract (33.4% of all blind people globally) and undercorrection of refractive error (20.9%) in the list of the most common causes of global blindness \[[@pone.0162229.ref036]\]. Glaucoma and macular degeneration ranked first in the list of most common irreversible causes of blindness. With respect to MSVI, glaucoma ranked fourth (2.2%) after undercorrection of refractive error (52.9% of all people with MSVI globally), cataract (18.4%) and macular degeneration (2.2%) in the list of the most common causes of MSVI worldwide. These data confirm previous studies and meta-analyses which showed that glaucoma had a prominent ranking in the frequency list of causes for blindness and visual impairment. In contrast to the previous landmark study by Quigley and Broman, glaucoma was ranked third and fourth in our study as compared to being ranked second by Quigley and Broman and more recently Pascolini et al. as cause for blindness worldwide \[[@pone.0162229.ref002],[@pone.0162229.ref041]\]. The numbers however also show that on a global perspective, cataract and undercorrection of refractive error are by far more prevalent as causes for blindness and MSVI. Only one out of 15 blind people was blind due to glaucoma, and only one out of 45 visually impaired people was visually impaired due to glaucoma. These figures may suggest that from a public health of view, providing adequate glasses for correction of refractive error and supplying cataract surgery to the blind and visually impaired may be at least as important as glaucoma care. In the recent meta-analysis of population-based studies by Tham and colleagues, the global prevalence of glaucoma in the population aged 40 to 80 years was 3.54% (95% Credible Intervals, 2.09, 5.82), and the number of individuals aged 40 to 80 years and affected by glaucoma worldwide was 64.3 million in the year 2013 \[[@pone.0162229.ref003]\]. These figures cannot directly be compared with the figures found in our investigation since Tham´s study addressed the number of individuals affected by glaucoma, independently of the stage of the disease, while our study assessed the number of individuals visually impaired or blind due to glaucoma.

The percentage of blindness caused by glaucoma showed regional variations, with relatively low figures in regions with relatively young populations such as South Asia and Sub-Saharan Africa, and with relatively high figures in regions with relatively old populations such as the high-income regions (Tables [1](#pone.0162229.t001){ref-type="table"} and [2](#pone.0162229.t002){ref-type="table"}). It was due to the dependence of the prevalence of glaucoma on age, while other causes for blindness and MSVI, namely undercorrection of refractive error and, to a lesser degree, cataract occurred also in younger groups of the population. These regional differences in the percentage of glaucoma as cause for blindness and MSVI remained mostly unchanged in the period from 1990 to 2010, since the differences in the age structure between the various world regions did not markedly change.

The global number of glaucoma blind increased by 0.8 million in the period from 1990 to 2010, although the age-standardized global prevalence of glaucoma related blindness in adults aged 50+ years decreased from 0.2% to 0.1%. The worldwide demographic transition with increasing population size, substantial increase in the average age in most regions and falling death rates more than outweighed the decrease in the prevalence of glaucoma related blindness so that the absolute numbers increased by 0.8 million or 62% from 1990 to 2010. The global prevalence of glaucoma related MSVI increased from 0.2% to 0.3% from 1990 to 2010, leading to marked increase in the absolute number of people visually impaired by glaucoma by 2.3 million or 83% in the same period. These figures show that, despite the relatively low percentage of glaucoma related blindness and MSVI on all causes of blindness and MSVI, an intensification of measures to address the growing number of people blind or visually impaired by glaucoma appears mandatory.

Expressed in percentage points, the age-standardized global prevalence of cataract, undercorrected refractive error and trachoma showed marked declines between 1990 and 2010 as reported previously \[[@pone.0162229.ref035]\]. The age-standardized prevalence of glaucoma declined less (for blindness) or even increased slightly (for MSVI). Similar findings were observed for the age-standardized prevalence of macular degeneration and diabetic retinopathy \[[@pone.0162229.ref035]\]. These developments may indicate a shift in the relative importance of the various diseases as causes for blindness and visual impairment, with a decrease for the major causes of cataract and undercorrection refractive error, which are relatively easily, safely and cost efficiently treatable, unlike diseases such as glaucoma, macular degeneration and diabetic retinopathy for which the therapy takes considerably more time and effort with a markedly lower rate of success.

Globally and in all regions, a larger percentage of blindness and MSVI caused by cataract and macular degeneration occurs in women than in men \[[@pone.0162229.ref036]\]. Globally, 36% of blindness among women was caused by cataract versus 30% of blindness among men; for MSVI, the figures were 20% versus 16%, respectively. In a similar manner, macular degeneration caused 7.3% of blindness among women versus 5.5% of blindness among men \[[@pone.0162229.ref036]\]. The glaucoma related blindness and MSVI did not show such marked disparities by sex in our study. This differs from the predictions of Quigley and Broman who estimated that 59% of all people with glaucoma of any stage would be women in 2010.

Literature reviews published by the WHO and the WHO Prevention of Blindness and Deafness program have previously been used to make worldwide estimates of numbers of people blind or with vision impairment. The latest of these studies included literature published in the period from 2000 to 2010 \[[@pone.0162229.ref041]\]. That analysis was limited to three age groups, with no breakdown by sex, provision of a point estimate for 2010, or estimates for the six WHO epidemiological subregions within a more limited timeframe. Interestingly, the figures for the percentage of blindness and MSVI caused by glaucoma did not markedly differ between Pascolini and Mariotti´s study and our study (glaucoma related blindness: 2% versus 2.2%; glaucoma related MSVI: 8% versus 6.0%) \[[@pone.0162229.ref041]\].

The present study forms part of a series of investigations on the prevalence and causes of vision loss in different world regions and on the number of individuals affected by MSVI and blindness caused by the major disorders of under-correction of refractive error, cataract, macular degeneration, diabetic retinopathy and glaucomatous optic neuropathy \[[@pone.0162229.ref042]--[@pone.0162229.ref051]\]. Applying the same statistical method (DisMod-MR) as the previous investigation, the present study addressed the number of individuals affected by glaucoma as cause for their MSVI or blindness. These figures may be of interest and help for politicians to direct financial means for the improvement of public health with respect to MSVI and blindness and to direct financial support for research in specific fields of medicine and in particular of ophthalmology. The previous studies of the series either assessed the worldwide prevalence of MSVI and blindness or examined the number of people affected by the main ocular disorders except for glaucomatous optic neuropathy.

The figure of 2.1 million individuals blind due to glaucoma and of 4.2 million individuals visually impaired due to glaucoma (representing 6.6% of all blindness and 2.2% of all MSVI worldwide) were lower than the figures of 10.8 million people blind and 35.1 million visually impaired due to cataract (representing 33.4% of all blindness and 18.4% of all MSVI worldwide), and also lower than the figures of 6.8 million people blind and 101.2 million people vision impaired due to undercorrected refractive errors (representing 20.9% of all blindness and 52.9% of all MSVI worldwide) \[[@pone.0162229.ref049],[@pone.0162229.ref051]\]. The figures of glaucoma associated blindness and MSVI were similar to the numbers of 2.1 million individuals blind and 6.0 million individuals visually impaired due to macular diseases (representing 6.6% of all blindness and 3.1% of all vision impairment) \[[@pone.0162229.ref048]\]. They were higher than the figures of 0.8 million people were blind due to diabetic retinopathy and 3.7 million visually impaired due to diabetic retinopathy (2.6% of all blindness and 1.9% of all MSVI worldwide) \[[@pone.0162229.ref050]\].

The design of our study had potential limitations. First, as we discussed in our report of global prevalence of vision loss, a significant limitation was that many country-years lacked data, or there was only sub-national data available \[[@pone.0162229.ref036]\]. Relatively few national studies reported vision impairment for all ages and for all causes. Second, some data sources did not present the prevalence by age. By imputing age-specific cause fractions we were able to utilize this data with the assumption that the age pattern of the vision impaired in the particular study matched the modeled age pattern in the country where the study was conducted \[[@pone.0162229.ref036]\]. Third, the majority of population-based studies within the database that reported on vision loss due to glaucoma did not disaggregate their reported findings into glaucoma diagnostic subtypes such as open-angle glaucoma and angle-closure glaucoma, therefore it was not possible to differentiate between glaucoma subtypes in our analysis. Fourth, protocol dictated that population-based studies will report one cause as the principal cause for an individual examined in that individual study, so that causal prevalence can be calculated. In situations where multiple disorders contribute equally to visual loss, only the ''most easily preventable" or the ''most readily curable" cause is usually recorded \[[@pone.0162229.ref052]\]. This approach can underestimate the impact of diseases such as diabetic retinopathy and glaucoma when a study participant presents with cataract, while underestimating cataract burden when study participants also have an uncorrected refractive error \[[@pone.0162229.ref053]\]. Finally, the relatively small sample size of some studies meant that the confidence intervals of cause-specific prevalence estimates were relatively large. Our methods did however take sample size into account, so small sample size studies had less influence on the estimates than larger studies. Strengths of this study included the large amount of population-based data accessed and utilized and the trend analysis of causes of vision impairment and blindness, usage of non-linear age trends and modeling of data that were not reported by age, systematic quantitative analysis and reporting of uncertainty intervals. The large size of network of ophthalmologic researchers involved in first identification and then evaluation of data sources allowed access to unpublished materials and permitted us to obtain additional unpublished data from study investigators who had only published summary data, to evaluate all the major vision impairment studies, and to include only studies that met specific inclusion criteria regarding population representativeness and clear description and definition of visual acuity procedures.

Conclusion {#sec009}
==========

In conclusion, in 2010, 2.1 million people were blind and 4.2 million people were visually impaired due to glaucoma. The number of people blind and visually impaired due to glaucoma increased by 0.8 million people or 62% and by 2.3 million people or 83%, respectively, in the period from 1990 to 2010. The contribution of glaucoma to total blindness and MSVI was higher in high-income regions with relatively older populations. One out of 15 blind people was blind due to glaucoma, and one out of 45 visually impaired people was visually impaired due to glaucoma.
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